- Home
- NKTX vs FLL Comparison
NKTX vs FLL Comparison
Compare NKTX & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- FLL
- Stock Information
- Founded
- NKTX 2015
- FLL 1987
- Country
- NKTX United States
- FLL United States
- Employees
- NKTX N/A
- FLL N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- FLL Hotels/Resorts
- Sector
- NKTX Health Care
- FLL Consumer Discretionary
- Exchange
- NKTX Nasdaq
- FLL Nasdaq
- Market Cap
- NKTX 123.5M
- FLL 128.2M
- IPO Year
- NKTX 2020
- FLL 1993
- Fundamental
- Price
- NKTX $2.37
- FLL $3.69
- Analyst Decision
- NKTX Strong Buy
- FLL Buy
- Analyst Count
- NKTX 5
- FLL 5
- Target Price
- NKTX $13.50
- FLL $5.80
- AVG Volume (30 Days)
- NKTX 556.1K
- FLL 190.0K
- Earning Date
- NKTX 08-12-2025
- FLL 08-07-2025
- Dividend Yield
- NKTX N/A
- FLL N/A
- EPS Growth
- NKTX N/A
- FLL N/A
- EPS
- NKTX N/A
- FLL N/A
- Revenue
- NKTX N/A
- FLL $297,653,000.00
- Revenue This Year
- NKTX N/A
- FLL $8.61
- Revenue Next Year
- NKTX N/A
- FLL $8.22
- P/E Ratio
- NKTX N/A
- FLL N/A
- Revenue Growth
- NKTX N/A
- FLL 8.24
- 52 Week Low
- NKTX $1.31
- FLL $2.86
- 52 Week High
- NKTX $6.63
- FLL $5.59
- Technical
- Relative Strength Index (RSI)
- NKTX 64.66
- FLL 42.22
- Support Level
- NKTX $2.23
- FLL $3.47
- Resistance Level
- NKTX $2.50
- FLL $3.72
- Average True Range (ATR)
- NKTX 0.13
- FLL 0.26
- MACD
- NKTX 0.02
- FLL -0.05
- Stochastic Oscillator
- NKTX 76.85
- FLL 32.31
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.